Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcus Biosciences, Inc.RCUS · Entity 4104 | Chief Financial Officer | May 11, 2026 | May 12, 2026 |
| Unity Biotechnology, Inc.UBX · Entity 77428 | Chief Financial Officer | June 22, 2020 | June 24, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcus Biosciences, Inc.
Report date May 11, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 84,161 |
Reported balance
After 2026-05-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-11 · Sale · Disposed 7,763 · Balance 84,161 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2: Includes the unvested portion of the reporting person's RSU grants. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: Includes the unvested portion of the reporting person's RSU grants.
Unity Biotechnology, Inc.
Report date June 22, 2020 · Filed June 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 161,027 |
Reported balance
After 2020-06-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-06-22 · Tax withholding · Disposed 2,483 · Balance 161,027 F1: The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the release of shares subject to vesting. F2: Includes Restricted Stock Units which vest over time measured from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the release of shares subject to vesting.
F2: Includes Restricted Stock Units which vest over time measured from the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CytomX Therapeutics, Inc.
Report date May 12, 2017 · Filed May 16, 2017
Section 16 reporting ended · disclosed 2017-05-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,756 |
Ending reported balance
After 2017-05-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-05-12 · Exercise / conversion · Acquired 9,980 · Balance 22,769 Row 2 · 2017-05-12 · Exercise / conversion · Acquired 9,987 · Balance 32,756 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.47 · Expires 2025-05-06 | Direct | 204,678 |
Reported balance
After 2017-05-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-05-12 · Exercise / conversion · Disposed 9,980 · Balance 204,678 F1: This option vests 25% on May 4, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on May 4, 2019. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.61 · Expires 2025-08-25 | Direct | 85,891 |
Reported balance
After 2017-05-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-05-12 · Exercise / conversion · Disposed 9,987 · Balance 85,891 F2: This option vests in 48 substantially equal monthly installments starting on August 28, 2015, with each additional installment vesting on the last day of the month starting in September 2015. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests 25% on May 4, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on May 4, 2019.
F2: This option vests in 48 substantially equal monthly installments starting on August 28, 2015, with each additional installment vesting on the last day of the month starting in September 2015.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2026 Filed May 12, 2026 20:09 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 7,763 | $25.63 | $198,965.69 |
DisclosureSEC source: 0001653881-26-000005 · wk-form4_1778616546.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,161 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes the unvested portion of the reporting person's RSU grants. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 01:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 96,000 | $0.00 Strike: $22.13 | $0.00 |
DisclosureSEC source: 0001653881-26-000002 · wk-form4_1769476886.xml · derivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock · 96,000 shares Expires 2036-01-22 F3 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 01:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001653881-26-000002 · wk-form4_1769476886.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,924 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. F2 · balance_after: Includes the unvested portion of the Reporting Person's RSU grants. Read SEC document |
| December 31, 2025 Filed Jan 2, 2026 21:19 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 6,552 | $23.38 | $153,185.76 |
DisclosureSEC source: 0001610717-26-000002 · form4.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,924 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 22:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 5,960 | $22.16 | $132,070.62 |
DisclosureSEC source: 0001653881-25-000011 · wk-form4_1766097319.xml · nonDerivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,476 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes the unvested portion of the reporting person's RSU grants. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 6,702 | $21.88 | $146,668.58 |
DisclosureSEC source: 0001653881-25-000011 · wk-form4_1766097319.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,436 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.42 to $22.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes the unvested portion of the reporting person's RSU grants. Read SEC document |
| November 26, 2025 Filed Nov 26, 2025 21:07 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 5,000 | $25.00 | $125,000.00 |
DisclosureSEC source: 0001653881-25-000007 · wk-form4_1764191259.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,138 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 12:54 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 5,000 | $20.00 | $100,000.00 |
DisclosureSEC source: 0001653881-25-000005 · wk-form4_1761742455.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,138 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2023. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:30 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $13.33 | $0.00 |
DisclosureSEC source: 0001724521-25-000017 · wk-form4_1738013415.xml · derivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2025-01-22 F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:30 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 37,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-25-000017 · wk-form4_1738013415.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,138 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2025, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:08 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 3,594 | $15.00 | $53,910.00 |
DisclosureSEC source: 0001724521-25-000002 · wk-form4_1735938476.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,138 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2023. Read SEC document |
| December 15, 2024 Filed Dec 18, 2024 01:36 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Tax withholdingCommon Stock | 10,099 | $16.08 | $162,391.92 |
DisclosureSEC source: 0001724521-24-000180 · wk-form4_1734485773.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,732 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 00:40 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 86,600 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001724521-24-000030 · wk-form4_1706229604.xml · derivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,600 Underlying: Common Stock · 86,600 shares Expires 2034-01-22 F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 00:40 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 21,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-24-000030 · wk-form4_1706229604.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,131 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2024 Filed Feb 23, 2024 22:49 UTC Amendment | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-24-000057 · wk-form4a_1708728574.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,831 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:23 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 2,004 | $20.00 | $40,080.00 |
DisclosureSEC source: 0001724521-24-000009 · wk-form4_1704406978.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,831 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2023. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 21:10 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 2,808 | $18.09 | $50,796.72 |
DisclosureSEC source: 0001724521-23-000067 · wk-form4_1703106591.xml · nonDerivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,835 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.78 to $18.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 21:10 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 2,749 | $17.74 | $48,767.26 |
DisclosureSEC source: 0001724521-23-000067 · wk-form4_1703106591.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,643 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.45 to $17.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:05 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 4,049 | $20.04 | $81,141.96 |
DisclosureSEC source: 0001209191-23-035740 · doc4.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,392 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2023. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:53 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 138,200 | $0.00 Strike: $22.02 | $0.00 |
DisclosureSEC source: 0001209191-23-004875 · doc4.xml · derivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,200 Underlying: Common Stock · 138,200 shares Expires 2033-01-22 F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2023, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:53 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004875 · doc4.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,441 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 16, 2022 Filed Dec 17, 2022 02:44 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 387 | $31.23 | $12,086.01 |
DisclosureSEC source: 0001209191-22-061762 · doc4.xml · nonDerivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,566 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.05 to $31.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 16, 2022 Filed Dec 17, 2022 02:44 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 2,066 | $30.66 | $63,343.56 |
DisclosureSEC source: 0001209191-22-061762 · doc4.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,953 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.05 to $31.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 22:08 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $33.03 | $0.00 |
DisclosureSEC source: 0001209191-22-017984 · doc4.xml · derivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2032-03-07 F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2022, subject to the Reporting Person's continued service to the Company. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 22:08 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 15,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017984 · doc4.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,519 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2022, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 21:22 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 224 | $41.42 | $9,278.93 |
DisclosureSEC source: 0001209191-21-070565 · doc4.xml · nonDerivative · entry 6 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,019 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F7 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.10 to $41.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 21:22 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 171 | $40.57 | $6,938.02 |
DisclosureSEC source: 0001209191-21-070565 · doc4.xml · nonDerivative · entry 5 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,243 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.10 to $41.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 21:22 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 88 | $39.67 | $3,491.13 |
DisclosureSEC source: 0001209191-21-070565 · doc4.xml · nonDerivative · entry 4 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,414 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.10 to $40.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 21:22 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 138 | $38.79 | $5,352.70 |
DisclosureSEC source: 0001209191-21-070565 · doc4.xml · nonDerivative · entry 3 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,502 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.10 to $39.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 21:22 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 131 | $40.46 | $5,299.80 |
DisclosureSEC source: 0001209191-21-070565 · doc4.xml · nonDerivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,640 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.12 to $40.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 21:22 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 354 | $39.59 | $14,015.43 |
DisclosureSEC source: 0001209191-21-070565 · doc4.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,771 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.11 to $40.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:10 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $36.73 | $0.00 |
DisclosureSEC source: 0001209191-21-004260 · doc4.xml · derivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-01-18 F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:10 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004260 · doc4.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| September 09, 2020 Filed Sep 9, 2020 20:53 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 5,000 | $21.57 | $107,848.50 |
DisclosureSEC source: 0001209191-20-049846 · doc4.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.10 to $22.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 22:53 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $21.06 | $0.00 |
DisclosureSEC source: 0001209191-20-044848 · doc4.xml · derivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-07-31 F1 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after August 1, 2020, subject to the Reporting Person's continued service to the Company. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 17:03 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | Tax withholdingCommon Stock, $0.0001 par value | 2,483 | $9.67 | $24,010.61 |
DisclosureSEC source: 0000899243-20-017558 · doc4.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,027 F1 · kind: The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the release of shares subject to vesting. F2 · balance_after: Includes Restricted Stock Units which vest over time measured from the grant date. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 17:16 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 118,188 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0000899243-20-009854 · doc4.xml · derivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,188 Underlying: Common Stock · 118,188 shares Expires 2030-03-29 F3 · derivative.exercise_date: Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on March 30, 2020 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 17:16 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantCommon Stock, $0.0001 par value | 29,106 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-009854 · doc4.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,510 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in equal annual installments over a three year period measured from March 30, 2020. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · balance_after: Includes RSUs which vest over time measured from the grant date. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 17:48 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0000899243-20-005933 · doc4.xml · derivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,620 Underlying: Common Stock · 10,000 shares Expires 2027-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vested on September 5, 2018 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 17:48 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | Exercise / conversionCommon Stock, $0.0001 par value | 10,000 | $3.43 | $34,300.00 |
DisclosureSEC source: 0000899243-20-005933 · doc4.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 relates to the exercise of an in-the-money stock option with cash by Reporting Person. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 20:01 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 28,814 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0000899243-19-024074 · doc4.xml · derivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,814 Underlying: Common Stock · 28,814 shares Expires 2027-09-25 F2 · shares: On September 26, 2017, Reporting Person was granted an option exercisable for 115,254 shares. Twenty-five percent (25%) of the shares was subject to vesting pursuant to the achievement of a clinical development milestone; in this case proof of concept that treatment with a senolytic drug meaningfully ameliorates a human disease. On September 19, 2019, Issuer's Board of Directors determined that such milestone was achieved. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 16:17 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 116,850 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013880 · doc1.xml · derivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,850 Underlying: Common Stock · 116,850 shares Expires 2029-06-19 F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 48 successive, equal monthly installments measured from June 20, 2019, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 16:17 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantCommon Stock | 21,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013880 · doc1.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,404 F1 · shares: RSUs which vest 1/3 annually over 3 years measured from June 20, 2019. F2 · balance_after: Includes 1,981 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2019. Read SEC document |
| October 10, 2018 Filed Oct 12, 2018 17:36 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0000899243-18-026655 · doc4.xml · derivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,620 Underlying: Common Stock · 5,000 shares Expires 2027-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vested on September 5, 2018 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| October 10, 2018 Filed Oct 12, 2018 17:36 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | Exercise / conversionCommon Stock, $0.0001 par value | 5,000 | $3.43 | $17,150.00 |
DisclosureSEC source: 0000899243-18-026655 · doc4.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:24 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionSeries C Preferred Stock · Derivative | 1,630 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022049 · doc1.xml · derivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,630 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. Read SEC document |
| May 07, 2018 Filed May 7, 2018 18:24 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | ConversionCommon Stock | 1,630 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-022049 · doc1.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| May 02, 2018 Filed May 4, 2018 18:26 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 30,508 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001140361-18-021820 · doc1.xml · derivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,508 Underlying: Common Stock · 30,508 shares Expires 2028-05-01 F1 · derivative.exercise_date: The shares subject to the option vest as to 25% of the shares on the one-year anniversary of May 2, 2018, and 1/48th of the shares shall vest on each monthly anniversary thereafter, subject to the optionee remainining a service provider to the Issuer on each such vesting date. Read SEC document |
| May 12, 2017 Filed May 16, 2017 20:57 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,987 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001140361-17-021016 · doc1.xml · derivative · entry 4 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,891 Underlying: Common Stock · 9,987 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vests in 48 substantially equal monthly installments starting on August 28, 2015, with each additional installment vesting on the last day of the month starting in September 2015. Read SEC document |
| May 12, 2017 Filed May 16, 2017 20:57 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,980 | $0.00 Strike: $4.47 | $0.00 |
DisclosureSEC source: 0001140361-17-021016 · doc1.xml · derivative · entry 3 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,678 Underlying: Common Stock · 9,980 shares Expires 2025-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option vests 25% on May 4, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on May 4, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.